Antiangiogenic drug is promising for radioiodine-refractory thyroid cancer
the ONA take:
Researchers at the University of Texas MD Anderson Cancer Center saw dramatic improvement in progression-free survival in patients with advanced radioiodine-refractory thyroid cancer who received the oral antiangiogenic lenvatinib in a phase III study.
The American Cancer Society estimates that thyroid cancer will be diagnosed in 62,450 in 2015, and 1,950 will die from the disease. Radioactive iodine has been the only treatment available to patients with metastatic thyroid disease.
Although the treatment is effective for some patients, more than half of patients do not respond to the therapy. In this international, randomized, phase III double-blind study, 392 patients with progressive, refractory thyroid cancer from 21 countries were randomized at a 2:1 ratio to receive either lenvatinib or a placebo.
The primary end point was progression-free survival; secondary end points tested response rate, overall survival, and safety. Study results included median progression-free survival of 18.3 months for those receiving lenvatinib vs 3.6 months for those receiving placebo; overall response rate was 64.8% (with four complete and 165 partial responses) vs 1.5%, respectively. Median overall survival was not reached in either group.
Side effects were reported for more than 40% of patients who received the study drug, with hypertension being the most common. Other side effects included diarrhea, fatigue, nausea, decreased appetite and weight.
Thirty-seven patients discontinued the drug because of the side effects, and 6 of 20 deaths that occurred during the study period were determined to be drug-related by the treating physicians.
Follow-up studies with lenvatinib and in combination with other novel therapies for radioiodine refractory disease, as well as in other types of thyroid cancers, are in development.
Dramatic improvement in progression-free survival in patients with advanced radioiodine-refractory thyroid cancer.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Robotic Surgery Provides Good Outcomes and Survival in Oropharyngeal Cancer
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|